SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

ABUS

Arbutus Biopharma Corporation
NEUTRAL
Impact 4/10
Horizonweeks Processed6d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The Moderna $1.3B contingent payment decision from the Federal Circuit is pending and represents the next major catalyst. Monitor the 10-Q filing for full details on the tender offer impact and ongoing litigation costs.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

ABUS drug pipeline →

AB-101

● Neutral Named in this press release
Impact
Phase
Phase 1a/1b
Time to market
AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
Next catalyst
None dated

What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.

Price Chart

Loading chart...

Executive Summary

Arbutus reported Q3 2026 net income of $59.1M ($0.30 per share) vs a net loss of $7.7M in Q3 2025, driven by a $67.3M dividend from Genevant. Revenue was $0.3M, below the $1.4M consensus. The company completed a $230M tender offer returning capital to shareholders and announced expanded LNP patent litigation against Pfizer/BioNTech.

Key Financial Metrics

EPS
$0.30
Revenue
$300.0K
est $1.4M · -78.6% · -40.0% YoY

Key Facts

  • Q3 2026 net income of $59.1M vs net loss of $7.7M in Q3 2025
  • Total revenue of $0.3M, down from $0.5M in Q3 2025 and below $1.4M consensus
  • Cash, cash equivalents and marketable securities of $337.5M as of Sept 30, 2026
  • Completed $230M tender offer in Oct 2026, repurchasing 46M shares (23% of outstanding) at $5.00/share
  • Received $67.3M cash dividend from Genevant in Sept 2026
  • Filed new LNP patent infringement lawsuits in Japan and amended Canadian case against Pfizer/BioNTech
  • FDA lifted clinical hold on AB-101 (oral PD-L1 inhibitor) IND in Oct 2026
  • Moderna settlement: $178.4M received in July 2026; $1.3B contingent payment awaits Federal Circuit ruling
  • R&D expenses fell to $2.6M from $5.8M due to workforce reduction and discontinued in-house research
  • G&A expenses rose to $8.0M from $3.0M due to one-time executive bonuses related to Moderna settlement

Financial Impact

Net income of $59.1M vs consensus EPS of -$0.03; revenue of $0.3M vs $1.4M consensus; cash position $337.5M

net incomerevenuecashshare count

Risk Factors

  • Revenue decline and reliance on non-recurring litigation income and dividends
  • Uncertainty around Moderna $1.3B contingent payment pending Federal Circuit ruling
  • Patent litigation against Pfizer/BioNTech is early-stage with no near-term resolution
  • Clinical-stage pipeline (imdusiran, AB-101) has no approved products and faces development risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399371

Track record

25 reports on ABUS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 Viewing No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026